Category

Australia

Daily Brief Australia: AUB Group Limited, WRKR, Qube Holdings and more

By | Australia, Daily Briefs

In today’s briefing:

  • Merger Arb Mondays (01 Dec) – AUB, Qube, NSR, Dongfeng, ENN, Jinke, ANE, Canon Electronics, Low Keng
  • WRKR Ltd – Solid Q1 FY26 with investment to ramp up
  • (Mostly) Asia M&A, Nov 2025 Wrap: Qube, Forum Engineering, National Storage REIT, Star Micronics



WRKR Ltd – Solid Q1 FY26 with investment to ramp up

By RaaS Research Group (RaaS)

  • Wrkr Ltd (ASX:WRK) offers compliance solutions for Australian superannuation contributions and payroll including member onboarding, super payments, messaging and employee validation.
  • WRK has delivered a record cash receipts quarter ($4.0m), +74% on the previous corresponding period (pcp) and +30% on Q4 FY25, aided by milestone payments and some overdue receipts from Q4 FY25 ($0.4m).
  • Total costs increased 24% on Q4 FY25 as WRK prepares for client onboarding and continues product development.

(Mostly) Asia M&A, Nov 2025 Wrap: Qube, Forum Engineering, National Storage REIT, Star Micronics

By David Blennerhassett

  • For November 2025, eight new transactions (firm and non-binding) were discussed on Smartkarma (by the Quiddity team) with an overall announced deal size of ~US$10bn.
  • The average premium for the new transactions announced (or first discussed) in November was ~31%, with a year-to-date average of ~48%.
  • The average premiums for transactions in 2024 (129 transactions), 2023 (117), 2022 (106), 2021 (165), 2020 (158), and 2019 (145 ) were 43%, 39%, 41%, 33%, 31%, and 31%.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Australia: S&P/ASX 200, Qube Holdings and more

By | Australia, Daily Briefs

In today’s briefing:

  • Australia Single Stock Options (Nov 24– 27): Broad Rebound Pulls Implieds Lower
  • Last Week In Event SPACE: Qube Holdings, Digital Holdings, Wynn Resorts/Macau, SNT/SMEC


Australia Single Stock Options (Nov 24– 27): Broad Rebound Pulls Implieds Lower

By John Ley

  • SPASX200 gained steadily through the week despite slowing daily momentum, nearly reversing last week’s decline
  • Market breadth strengthened, with a broad rebound across optionable stocks.
  • Implied vols declined across most single stocks, bringing the average back toward mid range levels after last week’s elevated readings

Last Week In Event SPACE: Qube Holdings, Digital Holdings, Wynn Resorts/Macau, SNT/SMEC

By David Blennerhassett

  • This deal for Qube Holdings (QUB AU) from Macquarie should really get competitive. Scarce and strategic assets  – and nothing else like it that’s listed. 
  • As Digital Holdings (2389 JP) goes higher, “This is Japan” risk increases; but those who didn’t sign up say “wait a minute, that’s real money” also goes up.
  • Wynn Resorts (WYNN US) is at extreme levels vs. Wynn Macau Ltd (1128 HK); yet consensus indicates considerably higher forward EBITDA growth for Resorts stub ops vs. Macau.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Australia: Fenix Resources and more

By | Australia, Daily Briefs

In today’s briefing:

  • Primer: Fenix Resources (FEX AU) – Nov 2025


Primer: Fenix Resources (FEX AU) – Nov 2025

By αSK

  • Fenix Resources is a rapidly growing, fully integrated iron ore producer in Western Australia, leveraging its wholly-owned logistics and port infrastructure to unlock stranded assets and maintain high margins.
  • The company’s recent acquisition of a 30-year mining right at the Weld Range project is transformational, securing a 290 million tonne resource base that significantly extends mine life and provides a clear pathway to scale production beyond 4 million tonnes per annum.
  • While the company trades at attractive valuation multiples and is poised for significant cash flow growth, its earnings are highly sensitive to the volatile global iron ore price, which remains the principal risk to the investment thesis.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Australia: Percheron Therapeutics and more

By | Australia, Daily Briefs

In today’s briefing:

  • Percheron Therapeutics — Phase II visibility drives valuation upgrade
  • Percheron Therapeutics — Phase II visibility drives valuation upgrade


Percheron Therapeutics — Phase II visibility drives valuation upgrade

By Edison Investment Research

We have refreshed our investment case for Percheron as the company heads into CY26 with a clearly defined Phase II plan for HMBD-002, backed by positive Phase I data and a strengthened management team. Our model now reflects the likely Phase II basket design, comprising exploratory and subsequent expansion cohorts, along with refined assumptions on study size, sequencing and timelines across the four priority indications: triple-negative breast cancer (TNBC), EGFR-mutant non-small cell lung cancer (NSCLC), HER2-negative oesophageal adenocarcinoma and endometrial cancer. With trial initiation likely to be staggered (we model a three- to six-month gap between each arm), we anticipate TNBC and NSCLC to be the lead indications, reflecting their larger addressable markets and clearer early-stage partnering interest. We expect the company to self-sponsor the Phase II studies with a global licensing deal in 2029, ahead of Phase III. Our valuation increases to A$79.0m or 7.3c/share, from A$66.7m or 6.1c/share.


Percheron Therapeutics — Phase II visibility drives valuation upgrade

By Edison Investment Research

We have refreshed our investment case for Percheron as the company heads into CY26 with a clearly defined Phase II plan for HMBD-002, backed by positive Phase I data and a strengthened management team. Our model now reflects the likely Phase II basket design, comprising exploratory and subsequent expansion cohorts, along with refined assumptions on study size, sequencing and timelines across the four priority indications: triple-negative breast cancer (TNBC), EGFR-mutant non-small cell lung cancer (NSCLC), HER2-negative oesophageal adenocarcinoma and endometrial cancer. With trial initiation likely to be staggered (we model a three- to six-month gap between each arm), we anticipate TNBC and NSCLC to be the lead indications, reflecting their larger addressable markets and clearer early-stage partnering interest. We expect the company to self-sponsor the Phase II studies with a global licensing deal in 2029, ahead of Phase III. Our valuation increases to A$79.0m or 7.3c/share, from A$66.7m or 6.1c/share.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Australia: National Storage REIT, BHP Group Ltd and more

By | Australia, Daily Briefs

In today’s briefing:

  • National Storage REIT (NSR AU): Brookfield and GIC’s Attractive NBIO at A$2.86
  • BHP: Few Viable Targets After Anglo Bid Abandoned


National Storage REIT (NSR AU): Brookfield and GIC’s Attractive NBIO at A$2.86

By Arun George

  • National Storage REIT (NSR AU) has received a non-binding proposal from Brookfield and GIC at A$2.86 per unit, a 26.5% premium to the undisturbed price.
  • The Board has granted exclusive due diligence until 7 December. A scheme offer would be conditional on FIRB, NZ OIO and ACCC approval. 
  • The offer is attractive as it represents an all-time high and implies a P/NTA of 1.11x. The short exclusivity period increases the odds of a binding proposal.

BHP: Few Viable Targets After Anglo Bid Abandoned

By Graeme Cunningham

  • BHP has abandoned a last minute bid for Anglo American, which will likely see the latter’s planned merger with Teck with proceed 
  • We consider other potential targets for BHP, all copper, concluding that most seem unlikely for now, especially with the company stating a focus on organic growth
  • BHP faces the risks of a decline in iron ore (consensus) and copper (non-consensus) prices in our view, while it trades at premium to the sector and above our DCF 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Australia: Iress Ltd, National Storage REIT, Intermin Resources, Island Pharmaceuticals , Monadelphous and more

By | Australia, Daily Briefs

In today’s briefing:

  • Iress (IRE AU): Suitors Engaged, But (Still) Nothing Firm
  • National Storage REIT (NSR AU) In Trading Halt Ahead Of Possible Brookfield/GIC Tilt
  • Horizon Minerals Ltd – Production Update
  • Island Pharmaceuticals Ltd – De-risking the commercial path
  • Primer: Monadelphous (MND AU) – Nov 2025


Iress (IRE AU): Suitors Engaged, But (Still) Nothing Firm

By David Blennerhassett

  • The board of Iress Ltd (IRE AU), a trading and wealth management software provider, has denied reports in an Australian article concerning a possible takeover from Blackstone. 
  • The article said that Blackstone was reportedly back in talks for a bid “that could be worth between $11 and $12 per share“. Iress’ share price promptly popped 8% yesterday. 
  • Iress is still very much in play as it “continues to engage with multiple parties“. 

National Storage REIT (NSR AU) In Trading Halt Ahead Of Possible Brookfield/GIC Tilt

By David Blennerhassett

  • Reportedly, Brookfield and Singapore’s GIC will make an Offer for National Storage REIT (NSR AU), Australia and New Zealand’s largest landlord of self-storage sites .
  • The AFR is reporting that Brookfield/GIC are on the cusp of launching a bid around NTA.  NSR entered into a trading halt this morning. 
  • Earlier this year, key peer Abacus Storage King (ASK AU) fielded an NBIO from Ki Corporation/Public Storage (PSA US) at a ~3% premium to NTA; however, Ki/PSA ultimately walked. 

Horizon Minerals Ltd – Production Update

By RaaS Research Group (RaaS)

  • Horizon Minerals Limited (ASX:HRZ) is an emerging junior gold producer with 1.8moz of gold resources located around the Kalgoorlie and Coolgardie regions of Western Australia.
  • HRZ has announced a production update for both the Boorara and Phillips Find JV mining operations.
  • The update details progression on mining and processing at both projects as well as further detail on forward expectations which we think helps guide investors towards understanding ultimate outcomes.

Island Pharmaceuticals Ltd – De-risking the commercial path

By RaaS Research Group (RaaS)

  • Island Pharmaceuticals Ltd (ASX:ILA) is an antiviral therapeutics company targeting infectious diseases.
  • The company has made two recent announcements that improve its chances of selling Galidesivir for Marburg to the US government, ahead of potential FDA clearance of the drug.
  • On 20 November 2025 it announced the appointment of leading Washington D.C. based federal government affairs and lobbying firm, Todd Strategy Group (TSG), to support US government engagement.

Primer: Monadelphous (MND AU) – Nov 2025

By αSK

  • Monadelphous is a leading Australian engineering group specializing in construction and maintenance services for the resources, energy, and infrastructure sectors. Its dual-division structure allows it to capture opportunities across the full asset lifecycle.
  • The company is experiencing a period of strong growth, driven by significant contract wins in its core markets, particularly in iron ore and energy. A robust project pipeline and strategic acquisitions are expected to support continued revenue momentum.
  • While exposed to the cyclical nature of the resources sector and persistent skilled labor shortages, Monadelphous‘ strong balance sheet, long-term client relationships with blue-chip companies, and diversification into renewable energy and critical minerals position it to navigate market uncertainties.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Australia: Qube Holdings, Monash IVF, Bluescope Steel, Technology One and more

By | Australia, Daily Briefs

In today’s briefing:

  • Qube Holdings (QUB AU): Macquarie’s NBIO at A$5.20
  • Monash IVF (MVF AU) Rejects Soul Patts/Genesis’ Offer
  • Bluescope (BSL AU) Vs. Short Sims (SGM AU): Pair Trade Back in Play
  • Technology One Ltd – Outlook Intact Post Tech1’s FY25 Punishment


Qube Holdings (QUB AU): Macquarie’s NBIO at A$5.20

By Arun George

  • Qube Holdings (QUB AU) has received a non-binding proposal from Macquarie Asset Management (MAM) at A$5.20 per share, a 27.8% premium to the undisturbed price.
  • The Board has granted exclusive due diligence until 1 February 2026 (or 15 February under certain circumstances). A scheme offer would be conditional on FIRB and ACCC approval. 
  • While the offer represents an all-time high, the scarcity value of high-quality infrastructure assets could spur a competing bid from others, such as Brookfield, which holds pre-emptive rights at Patrick.

Monash IVF (MVF AU) Rejects Soul Patts/Genesis’ Offer

By David Blennerhassett

  • Monash IVF (MVF AU), a fertility provider, has announced, and summarily rejected, a A$0.80/share non-binding indicative Offer from Washington H. Soul Pattinson and Co. Ltd (SOL AU) & Genesis Capital.
  • The indicative terms are a ~31% premium to last close. And ~7.7x FY25 EV/EBITDA. Chairman Richard Davis declared terms “opportunistic in timing and materially undervalues the company“. 
  • Genesis/Soul Patts collectively hold 19.6% in MVF.  MVF’s share price has cratered this year after a woman was mistakenly implanted with the wrong embryo. The CEO subsequently stepped down. 

Bluescope (BSL AU) Vs. Short Sims (SGM AU): Pair Trade Back in Play

By Gaudenz Schneider

  • Context: The Bluescope Steel (BSL AU) vs. Sims Metal Management (SGM AU) price-ratio has deviated two standard deviations from its one-year average, presenting a potential relative value opportunity.
  • Highlights: Going long Bluescope (BSL AU) and short Sims (SGM AU) targets a 6% return.
  • Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.

Technology One Ltd – Outlook Intact Post Tech1’s FY25 Punishment

By FNArena

  • Shares in TechnologyOne reacted negatively on the release of a record FY25 performance, as not all metrics met elevated expectations and as the global technology sector is de-rated.
  • -TechnologyOne delivers record FY25 metrics -Profit exceeds guidance, strong UK growth -Market concerns on softer than expected ARR and NRR -Global de-rating for the sector equally impacts on updated valuations/price targets

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Australia: Monash IVF, Qube Holdings, Webjet Group, BHP Group Ltd, Fenix Resources , Technology One and more

By | Australia, Daily Briefs

In today’s briefing:

  • Monash IVF (MVF AU): Genesis Capital to Launch a Takeover Proposal?
  • Qube (QUB AU): Macquarie’s Lobs NBIO
  • Webjet Group (WJL AU): BGH Capital Counters Helloworld with a Competing Proposal
  • Relative Value Opportunities in Asia-Pac, Pair Trade Roundup (24 Nov)
  • Iron Ore At 104 USD/Ton: Where To Now With Simandou Online? Still Like Fenix, Others Fairly Valued
  • Technology One Ltd – Outlook Intact Post Tech1’s FY25 Punishment


Monash IVF (MVF AU): Genesis Capital to Launch a Takeover Proposal?

By Arun George

  • The AFR reports that a mystery buyer, believed to be Genesis Capital, will launch a takeover proposal for Monash IVF (MVF AU) at A$0.80, a 31.1% premium to the last close.
  • On Friday, the mystery buyer acquired a pre-bid stake of 6.01% of outstanding shares at A$0.80. The timing is opportunistic as the shares are down 51% YTD.
  • It is unclear whether Genesis is aiming to launch a scheme or an off-market takeover offer. Nevertheless, the rumoured offer is light. 

Qube (QUB AU): Macquarie’s Lobs NBIO

By David Blennerhassett

  • Qube Holdings (QUB AU), a logistics and infrastructure play, has announced a A$5.20/share non-binding indicative Offer from Macquarie Asset Management, a unit of Macquarie Group (MQG AU).
  • That is a 27.8% premium to last close. And ~14.4x FY25 EV/EBITDA. The proposal “follows an earlier unsolicited, non-=binding and indicative offer at lower value.” Dividends paid will be netted.
  • Qube directors are supportive. The proposal is conditional on due diligence, board approvals, no MACs at Qube, plus regulatory clearance, including FIRB and ACCC signing off.

Webjet Group (WJL AU): BGH Capital Counters Helloworld with a Competing Proposal

By Arun George

  • On 21 November, Webjet Group (WJL AU) disclosed a non-binding takeover offer from BGH Capital at A$0.91 per share, a 1.1% premium to the Helloworld Ltd (HLO AU) offer.
  • BGH’s takeover offer is conditional on a 75% minimum acceptance condition, which is too high a threshold to meet. The acceptance condition is likely to be revised to 50.1%.     
  • Helloworld has justification to engage in a bidding war, particularly due to potential synergies and multiple re-rating. I would expect at least another round of bids. 

Relative Value Opportunities in Asia-Pac, Pair Trade Roundup (24 Nov)

By Gaudenz Schneider

  • Context: This Insight follows up on previously highlighted relative value opportunities, using a statistical methodology based on mean-reversion to identify opportunities in paired securities.
  • Highlights: Currently twelve pair trade opportunities across three markets and five sectors persist.
  • Why read: Statistical analysis offers a unique perspective on relative value. Gain insights into actionable statistical pair trade opportunities and monitor performance of previously highlighted pairs.

Iron Ore At 104 USD/Ton: Where To Now With Simandou Online? Still Like Fenix, Others Fairly Valued

By Sameer Taneja

  • Iron ore prices have remained rock-solid at 104 USD/ton, but the fundamentals are on slightly shaky ground as Rio Tinto (RIO US) commenced shipments from its Simandou project. 
  • Chinese steel production and apparent demand in October tracked an extremely weak 12%/12.5% YoY, with annualized production rates now 864 million tons, and lending (TSF) was lacklustre at -42% YoY.
  • We like Fenix Resources (FEX AU) despite the negative sentiment, due to its production growth profile from 4 million to 10 million tons over the next 3 years. 

Technology One Ltd – Outlook Intact Post Tech1’s FY25 Punishment

By FNArena

  • Shares in TechnologyOne reacted negatively on the release of a record FY25 performance, as not all metrics met elevated expectations as as the global technology sector is de-rated.
  • -TechnologyOne delivers record FY25 metrics -Profit exceeds guidance, strong UK growth -Market concerns on softer than expected ARR and NRR -Global de-rating for the sector equally impacts on updated valuations/price targets

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Australia: DXN Ltd, Future Metals NL, Keybridge Capital, RMA Global Ltd and more

By | Australia, Daily Briefs

In today’s briefing:

  • Primer: DXN Ltd (DXN AU) – Nov 2025
  • Primer: Future Metals NL (FME AU) – Nov 2025
  • Primer: Keybridge Capital (KBC AU) – Nov 2025
  • Primer: RMA Global Ltd (RMY AU) – Nov 2025


Primer: DXN Ltd (DXN AU) – Nov 2025

By αSK

  • DXN Ltd is a specialist in the design, manufacturing, and operation of prefabricated modular data centers, positioning itself as an agile solution provider in the growing edge computing and data infrastructure market.
  • The company has demonstrated strong revenue growth, with a 49% increase to $16.0 million in FY25, driven by its Modular Division and the launch of a new Data Centre as a Service (DCaaS) division aimed at generating recurring revenue.
  • Despite revenue growth, DXN remains unprofitable, reporting a net loss of $2.3 million in FY25. The company’s financial stability is a key concern, underscored by persistent losses and negative operating cash flow in the most recent fiscal year.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Primer: Future Metals NL (FME AU) – Nov 2025

By αSK

  • Future Metals NL is an exploration-stage company focused on its 100% owned Panton PGM-Nickel Project in Western Australia, which is considered the highest-grade PGM deposit in Australia.
  • The Panton project has a significant JORC Mineral Resource Estimate of 4.5 million ounces of PGM and 185,000 tonnes of nickel, positioning it as a globally significant PGM resource outside of the primary supply jurisdictions of Russia and South Africa.
  • While the project shows robust economics in a December 2023 Scoping Study, the company is currently pre-revenue and faces the typical risks of an exploration company, including financing, development, and commodity price risks.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Primer: Keybridge Capital (KBC AU) – Nov 2025

By αSK

  • Keybridge Capital is a small, opportunistic investment company with a highly volatile financial track record, characterized by significant swings in revenue and profitability.
  • The company’s strategy involves a diversified portfolio of equity and debt investments, with a recent history of engaging in specialized situations like stablecoin arbitrage and activist investing, exemplified by a profitable exit from Magellan Global Fund Options.
  • Extreme financial volatility, negative cash flows, a no-dividend policy to date, and a highly concentrated management structure present significant risks for investors, despite a recent profitable year and very low valuation multiples.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Primer: RMA Global Ltd (RMY AU) – Nov 2025

By αSK

  • RMA Global operates a digital marketing and reputation management platform, RateMyAgent, for real estate professionals, with its primary revenue generated from agent subscriptions and promotional products.
  • The company has demonstrated strong revenue growth, particularly in the US market, and has successfully reduced its net loss in the most recent fiscal year.
  • Despite revenue growth, the company remains unprofitable and has a history of negative operating and free cash flow, indicating a continued reliance on external funding or cash reserves to sustain operations.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Australia: Clarity Pharmaceuticals Ltd, ALS Ltd, JB Hi-Fi Ltd and more

By | Australia, Daily Briefs

In today’s briefing:

  • Quiddity Leaderboard ASX Dec25: Reference Period Ending Soon; Some Surprises Possible
  • ALS Strikes Gold, With Upside Potential
  • JB Hi-Fi (JBH AU) Vs. Wesfarmers (WES AU): Statistical Arbitrage as Spread Hits Three-Sigma


Quiddity Leaderboard ASX Dec25: Reference Period Ending Soon; Some Surprises Possible

By Janaghan Jeyakumar, CFA

  • In this insight, we take a look at the potential index changes for ASX 200, 100, 50, and 20 in the run-up to the December 2025 index rebal event.
  • We expect two changes for ASX 50, two changes for ASX 100, and seven changes for ASX 200.
  • The official index changes will be announced after the close on Friday 5th December 2025.

ALS Strikes Gold, With Upside Potential

By FNArena

  • Rising demand for commodities testing, supported by the soaring gold price, provided a strong first half for ALS Ltd, and it appears there’s more to come.
  • -ALS Ltd first half beat expectations -Better than expected growth in minerals testing -Junior miners set to begin exploration, increasing demand -Guidance seen as conservative

JB Hi-Fi (JBH AU) Vs. Wesfarmers (WES AU): Statistical Arbitrage as Spread Hits Three-Sigma

By Gaudenz Schneider

  • Context: The JB Hi-Fi (JBH AU) vs. Wesfarmers  (WES AU) price ratio has deviated more than three standard deviations from its one-year average, presenting a potential relative value opportunity.
  • Highlights: Going long JB Hi-Fi (JBH AU) and short Wesfarmers (WES AU) targets a 6% return.
  • Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars